Literature DB >> 11435556

Molecular basis for cell tropism of CXCR4-dependent human immunodeficiency virus type 1 isolates.

K Tokunaga1, M L Greenberg, M A Morse, R I Cumming, H K Lyerly, B R Cullen.   

Abstract

Laboratory isolates of human immunodeficiency virus type 1 (HIV-1) that utilize CXCR4 as a coreceptor infect primary human macrophages inefficiently even though these express a low but detectable level of cell surface CXCR4. In contrast, infection of primary macrophages by primary CXCR4-tropic HIV-1 isolates is readily detectable. Here, we provide evidence suggesting that this difference in cell tropism results from a higher requirement for cell surface CXCR4 for infection by laboratory HIV-1 isolates. Transfected COS7 cells that express a high level of CD4 but a low level of CXCR4 were infected significantly more efficiently by two primary CXCR4-tropic HIV-1 isolates compared to the prototypic laboratory HIV-1 isolate IIIB. More importantly, overexpression of either wild-type or signaling-defective CXCR4 on primary macrophages dramatically enhanced the efficiency of infection by the laboratory HIV-1 isolate yet only modestly enhanced infection by either primary CXCR4-tropic virus. Overexpression of CD4 had, in contrast, only a limited effect on macrophage infection by the laboratory HIV-1, although infection by the primary isolates was markedly enhanced. We therefore conclude that the laboratory CXCR4-tropic HIV-1 isolate exhibits a significantly higher CXCR4 requirement for efficient infection than do the primary CXCR4-tropic isolates and that this difference can explain the poor ability of the laboratory HIV-1 isolate to replicate in primary macrophages. More generally, we propose that the cell tropisms displayed by different strains of HIV-1 in culture can largely be explained on the basis of differential requirements for cell surface CD4 and/or coreceptor expression levels.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11435556      PMCID: PMC114404          DOI: 10.1128/JVI.75.15.6776-6785.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop.

Authors:  T M Ross; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

2.  AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

Authors:  G A Donzella; D Schols; S W Lin; J A Esté; K A Nagashima; P J Maddon; G P Allaway; T P Sakmar; G Henson; E De Clercq; J P Moore
Journal:  Nat Med       Date:  1998-01       Impact factor: 53.440

3.  HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import.

Authors:  R A Fouchier; B E Meyer; J H Simon; U Fischer; M H Malim
Journal:  EMBO J       Date:  1997-08-01       Impact factor: 11.598

4.  CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages.

Authors:  G Simmons; J D Reeves; A McKnight; N Dejucq; S Hibbitts; C A Power; E Aarons; D Schols; E De Clercq; A E Proudfoot; P R Clapham
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

5.  Identification of CXCR4 domains that support coreceptor and chemokine receptor functions.

Authors:  B J Doranz; M J Orsini; J D Turner; T L Hoffman; J F Berson; J A Hoxie; S C Peiper; L F Brass; R W Doms
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  CXCR-4 is expressed by primary macrophages and supports CCR5-independent infection by dual-tropic but not T-tropic isolates of human immunodeficiency virus type 1.

Authors:  Y Yi; S Rana; J D Turner; N Gaddis; R G Collman
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

7.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

8.  Differential cross-regulation of the human chemokine receptors CXCR1 and CXCR2. Evidence for time-dependent signal generation.

Authors:  R M Richardson; B C Pridgen; B Haribabu; H Ali; R Snyderman
Journal:  J Biol Chem       Date:  1998-09-11       Impact factor: 5.157

9.  CXCR4 is a functional coreceptor for infection of human macrophages by CXCR4-dependent primary HIV-1 isolates.

Authors:  A Verani; E Pesenti; S Polo; E Tresoldi; G Scarlatti; P Lusso; A G Siccardi; D Vercelli
Journal:  J Immunol       Date:  1998-09-01       Impact factor: 5.422

10.  Human immunodeficiency virus type 1 T-lymphotropic strains enter macrophages via a CD4- and CXCR4-mediated pathway: replication is restricted at a postentry level.

Authors:  H Schmidtmayerova; M Alfano; G Nuovo; M Bukrinsky
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

View more
  37 in total

1.  Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.

Authors:  Tara G Edmonds; Haitao Ding; Xing Yuan; Qing Wei; Kendra S Smith; Joan A Conway; Lindsay Wieczorek; Bruce Brown; Victoria Polonis; John T West; David C Montefiori; John C Kappes; Christina Ochsenbauer
Journal:  Virology       Date:  2010-09-21       Impact factor: 3.616

2.  Complex determinants in human immunodeficiency virus type 1 envelope gp120 mediate CXCR4-dependent infection of macrophages.

Authors:  Guity Ghaffari; Daniel L Tuttle; Daniel Briggs; Brant R Burkhardt; Deepa Bhatt; Warren A Andiman; John W Sleasman; Maureen M Goodenow
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

3.  Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.

Authors:  Eric G Meissner; Vernon M Coffield; Lishan Su
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

Review 4.  Early events of HIV-1 infection: can signaling be the next therapeutic target?

Authors:  Kate L Jones; Redmond P Smyth; Cândida F Pereira; Paul U Cameron; Sharon R Lewin; Anthony Jaworowski; Johnson Mak
Journal:  J Neuroimmune Pharmacol       Date:  2011-03-05       Impact factor: 4.147

Review 5.  The macrophage response to HIV-1: Intracellular control of X4 virus replication accompanied by activation of chemokine and cytokine synthesis.

Authors:  Iqbal H Chowdhury; Galina Bentsman; Wonkyu Choe; Mary Jane Potash; David J Volsky
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

6.  HIV-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes.

Authors:  Yukie Iwabu; Hideaki Fujita; Masanobu Kinomoto; Keiko Kaneko; Yukihito Ishizaka; Yoshitaka Tanaka; Tetsutaro Sata; Kenzo Tokunaga
Journal:  J Biol Chem       Date:  2009-10-16       Impact factor: 5.157

7.  Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus.

Authors:  Brian J Willett; Elizabeth L McMonagle; Nicola Logan; Pascal Schneider; Margaret J Hosie
Journal:  Mol Immunol       Date:  2009-02-01       Impact factor: 4.407

Review 8.  Chemokine receptors and co-stimulatory molecules: unravelling feline immunodeficiency virus infection.

Authors:  Brian J Willett; Margaret J Hosie
Journal:  Vet Immunol Immunopathol       Date:  2008-01-19       Impact factor: 2.046

9.  Plectin regulates the signaling and trafficking of the HIV-1 co-receptor CXCR4 and plays a role in HIV-1 infection.

Authors:  Yun Ding; Li Zhang; J Shawn Goodwin; Ziqing Wang; Bingdong Liu; Jingwu Zhang; Guo-Huang Fan
Journal:  Exp Cell Res       Date:  2007-11-17       Impact factor: 3.905

10.  Envelope variants from women recently infected with clade A human immunodeficiency virus type 1 confer distinct phenotypes that are discerned by competition and neutralization experiments.

Authors:  Sally L Painter; Roman Biek; David C Holley; Mary Poss
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.